FDA gives a mixed response to a petition seeking greater clinical trial transparency
The FDA will not enforce stricter measures against clinical trial sponsors and investigators failing to register studies or report results, citing resource constraints. It prefers voluntary compliance and regulatory discretion, while agreeing to create a dashboard for non-compliance notices.
Reference News
FDA gives a mixed response to a petition seeking greater clinical trial transparency
The FDA will not enforce stricter measures against clinical trial sponsors and investigators failing to register studies or report results, citing resource constraints. It prefers voluntary compliance and regulatory discretion, while agreeing to create a dashboard for non-compliance notices.